Surgery to improve liver function in cirrhosis patients
The Effect of Laparoscopic Splenectomy and Azygoportal Disconnection on Liver Reserve Function for Cirrhosis Patients
NA · Northern Jiangsu People's Hospital · NCT05325437
This study tests whether a specific surgery can help improve liver function in patients with cirrhosis who have an enlarged spleen.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Northern Jiangsu People's Hospital (other) |
| Locations | 1 site (Yangzhou, Jiangsu) |
| Trial ID | NCT05325437 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of laparoscopic splenectomy and azygoportal disconnection on liver reserve function in patients with cirrhosis. Patients diagnosed with cirrhosis and experiencing splenomegaly and secondary hypersplenism will undergo the surgical procedure, followed by a standardized postoperative treatment plan. Liver function indicators will be monitored at various intervals post-surgery to assess improvements in liver reserve function and overall patient prognosis.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with cirrhosis who have splenomegaly and secondary hypersplenism.
Not a fit: Patients with hepatocellular carcinoma, Child-Pugh grade C, or other significant comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance liver function and improve outcomes for patients with cirrhosis.
How similar studies have performed: While similar surgical approaches have been explored, this specific combination of procedures and its effects on liver reserve function is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * A clinical, radiological or histologic diagnosis of cirrhosis of any etiology * Splenomegaly with secondary hypersplenism * gastroesophageal variceal bleeding * Informed consent to participate in the study Exclusion Criteria: * Hepatocellular carcinoma or any other malignancy, * Child-Pugh grade C * Recent peptic ulcer disease * History of Hemorrhagic stroke * Pregnancy. * Uncontrolled Hypertension * Human immunodeficiency virus (HIV) infection
Where this trial is running
Yangzhou, Jiangsu
- Clinical Medical College of Yangzhou University — Yangzhou, Jiangsu, China (RECRUITING)
Study contacts
- Study coordinator: Guo-Qing Jiang, MD
- Email: jgqing2003@hotmail.com
- Phone: +8651487373272
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cirrhosis, Liver, Splenectomy, Status, Portal Hypertension, Cirrhosis, Azygoportal disconnection, Laparoscopy, Liver Reserve Function